Alcon Agrees to Acquire LENSAR, Inc.

Alcon Agrees to Acquire STAAR Surgical Company

October 15, 2025

Healthcare Services

Alcon entered into a definitive merger agreement to acquire STAAR Surgical Company for $28.00 per share in cash, valuing the deal at approximately $1.5 billion. The transaction includes STAAR’s EVO family of implantable collamer lenses (EVO ICL) and is expected to close in about six to 12 months, subject to regulatory approval and STAAR shareholder approval.

Alcon to Acquire LumiThera

July 7, 2025

Medical Devices

Alcon, a leader in eye care, plans to acquire LumiThera, which develops light-based therapies for ophthalmology, including its photobiomodulation (PBM) device for treating early and intermediate dry age-related macular degeneration (AMD). The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions and a LumiThera shareholder vote.

Alcon Acquires Aerie Pharmaceuticals, Inc.

August 22, 2022

Healthcare Services

Alcon entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, adding Rocklatan and Rhopressa commercial products along with AR-15512 and other ophthalmic pharmaceutical pipeline assets. The deal was funded with debt and was expected to close in Q4 2022, subject to customary approvals and conditions.

Luminar Technologies Acquires Freedom Photonics

March 21, 2022

Industrial Services

Luminar (Nasdaq: LAZR) announced it is acquiring Freedom Photonics, a high-performance laser chip and photonics components company used for lidar and other optical sensing applications. The all-stock deal follows years of collaboration and is expected to close in the second quarter, with Freedom Photonics’ leadership continuing to run and expand the business after closing.

Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B

March 3, 2021

Medical Devices

Boston Scientific has agreed to acquire the Lumenis Surgical Business from Baring Private Equity Asia/Lumenis for USD 1.07 billion, subject to closing adjustments. The deal transfers Lumenis' surgical laser portfolio and global surgical team (including its Israeli laser center of excellence) to Boston Scientific to bolster its Urology strategy, while Lumenis — still owned by BPEA — will focus on Aesthetics and Vision.

Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals

May 23, 2022

Pharmaceuticals

Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.